Compare DENN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DENN | CTNM |
|---|---|---|
| Founded | 1953 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.8M | 328.1M |
| IPO Year | 1989 | 2024 |
| Metric | DENN | CTNM |
|---|---|---|
| Price | $6.17 | $11.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $5.45 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.7M | 169.9K |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $457,212,000.00 | N/A |
| Revenue This Year | $6.56 | N/A |
| Revenue Next Year | $1.56 | N/A |
| P/E Ratio | $31.51 | ★ N/A |
| Revenue Growth | ★ 0.93 | N/A |
| 52 Week Low | $2.85 | $3.35 |
| 52 Week High | $7.66 | $15.25 |
| Indicator | DENN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 65.68 | 49.67 |
| Support Level | $6.13 | $10.42 |
| Resistance Level | $6.20 | $11.43 |
| Average True Range (ATR) | 0.02 | 0.80 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 64.29 | 28.10 |
Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.